Author

María García Donday

IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT)
IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT)

María García Donday  et al.

Item 1 - 1 / 1
1